Quick Facts: Therapeutic Areas

• Adult and Pediatric Plaque Psoriasis: Addresses moderate to severe plaque psoriasis in patients who may require systemic treatment or phototherapy.
• Psoriatic Arthritis (PsA): Used to manage active psoriatic arthritis, which may be administered alone or in combination with other agents like methotrexate.
• Ankylosing Spondylitis (AS): Indicated for the care of active ankylosing spondylitis in adult patients.
• Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Used for adult patients with active disease who show objective signs of inflammation.
• Enthesitis-Related Arthritis (ERA): Provides therapeutic support for active enthesitis-related arthritis in pediatric patients four years of age and older.
• Hidradenitis Suppurativa (HS): Indicated for the management of moderate to severe active hidradenitis suppurativa in adult patients.

---

What Secukinumab Treats: Main Uses and Benefits

Secukinumab is a medication prescribed to address several inflammatory conditions. Its primary purpose is to help manage the symptoms and manifestations of chronic autoimmune diseases.

In dermatology, it is indicated for the care of moderate to severe plaque psoriasis in both adults and children over the age of six who are candidates for systemic therapy or light treatment. Its use in this context is intended to reduce the appearance and extent of skin lesions.

The drug is also an established treatment for rheumatologic conditions. It is used in adults and children two years of age and older to manage active psoriatic arthritis (PsA). Furthermore, Secukinumab is used to help adult patients with active ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) that demonstrates signs of inflammation. For younger patients, it provides a therapeutic option for active enthesitis-related arthritis (ERA).

Finally, Secukinumab is prescribed for adult patients with moderate to severe active hidradenitis suppurativa (HS).

Secukinumab eligibility is strictly defined by regulatory approval for specific conditions and includes mandatory exclusion criteria.

Eligibility and Exclusion Criteria

Classification	Who Cannot Use the Medicine (Contraindications)
Absolute Prohibition	Previous serious hypersensitivity reaction to secukinumab or any excipient.
Infection Risk	Patients with a clinically important, active infection, including active tuberculosis (TB) infection.
Live Vaccines	Concurrent administration with live vaccines is prohibited.

Special Considerations

Population Group	Use Status
Inflammatory Bowel Disease (IBD)	Caution is advised; the drug is generally not recommended for patients with active IBD, and close monitoring is required.
Chronic/Recurrent Infection	Caution is advised for patients with a history of chronic or recurrent infection.
Latent Tuberculosis	Must initiate treatment for latent TB prior to starting secukinumab.
Pregnancy/Lactation	Use is preferably avoided during pregnancy due to limited data. Women of childbearing potential must use effective contraception during treatment and for 20 weeks after. A decision to discontinue breastfeeding or discontinue the drug must be made.

Age Requirements (Varies by Condition)

Secukinumab is approved for: Psoriatic Arthritis (patients 2 years and older); Enthesitis-Related Arthritis (4 years and older); Plaque Psoriasis (6 years and older). Other indications, such as Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis, and Hidradenitis Suppurativa, are approved for use in adults (generally 18 years and older).

Secukinumab’s official interaction profile focuses on restrictions related to additive immune effects and its lack of interference with major drug-metabolizing enzymes.

Interaction-Related Restrictions

The co-administration of live vaccines is formally contraindicated due to the immunosuppressive nature of the medicine, which may increase the risk of infection or reduce vaccine efficacy. Regulatory information specifies that all age-appropriate immunizations should be completed prior to initiating therapy. Conversely, inactivated or non-live vaccines may be administered, as studies found no suppression of the immune response to these types of vaccines.

Interactions with Other Medications

Combination use with other biologic immunosuppressants or Janus Kinase (JAK) inhibitors is generally restricted or has not been fully evaluated in regulatory studies due to the potential for an additive increase in the risk of serious infection. However, no clinically significant interaction was observed when Secukinumab was administered concurrently with conventional systemic treatments such as Methotrexate and Corticosteroids.

Metabolic Interaction Profile

Secukinumab does not show a clinically relevant interaction with the CYP3A4 drug-metabolizing enzyme, based on regulatory studies using a probe substrate. This finding formally indicates that Secukinumab is unlikely to alter the blood concentrations of other medicines primarily cleared by this major metabolic pathway. A theoretical consideration exists that by reducing inflammation, Secukinumab may normalize the formation of certain CYP enzymes, which could potentially affect the exposure of co-medications with a narrow therapeutic index.

Specific Neutralization of the IL-17A Cytokine

Secukinumab is a monoclonal antibody that acts by specifically binding to and neutralizing the pro-inflammatory signaling molecule, Interleukin-17A (IL-17A). By physically binding to free IL-17A in the extracellular space, the drug prevents the cytokine from attaching to its corresponding receptor (IL-17RA) located on the surface of various target cells . This neutralization step prevents the initiation of the inflammatory signal.

---

Inhibition of the Inflammatory Signaling Cascade

This binding action results in the inhibition of the IL-17 pathway. Preventing the IL-17A signal from activating the receptor complex interrupts a specific intracellular signaling cascade. This interruption restricts the activation of transcription factors that normally regulate the genetic programs of inflammation, thereby reducing the gene expression and production of numerous downstream inflammatory mediators (including other cytokines and chemokines).

---

Modulation of Cellular Hyperactivity

By restricting the downstream effects of excessive IL-17A activity, the drug modulates cellular hyperactivity. This includes the limitation of accelerated growth and turnover in certain tissue cells, such as keratinocytes. This targeted modulation of the overactive pathway supports the regulation of these specific cellular and tissue processes.

Administration Overview

Secukinumab is typically administered through subcutaneous injection, which involves delivering the medication into the fatty tissue layer just beneath the skin. Common injection sites include the front of the thighs, the abdomen, or the outer upper arms. It is important to rotate the injection sites for each dose to maintain skin health and ensure consistent absorption.

Preparation for Use

Before administration, the medication is usually removed from refrigeration and allowed to reach room temperature naturally. This process generally takes about 15 to 30 minutes. The medication should be inspected for clarity; it should appear clear to slightly opalescent and colorless to slightly yellow. It is standard practice to avoid shaking the solution and to ensure the liquid does not contain large particles or visible discoloration.

Self-Administration and Assistance

While the first injections are often performed by a healthcare professional, individuals may be trained to perform the injections themselves at home. If a patient is unable to perform the injection, a caregiver can be trained to assist. Proper hygiene, such as washing hands and cleaning the injection site with an alcohol swab, is a fundamental part of the process.

Handling and Storage

Secukinumab must be stored according to specific temperature requirements, typically in a refrigerator, and protected from light. Once a syringe or pen is removed from the refrigerator for use, it should not be put back. Any unused portion of the medication must be disposed of according to local guidelines for sharps and biohazardous waste.

Research Evidence / Overview of Studies for Secukinumab

Evidence Overview: Plaque Psoriasis Research

Secukinumab was studied for use in adults and children (age six and older) whose condition is characterized by fluctuating or episodic manifestations where systemic treatment has been studied. Research focused on assessing changes in skin symptoms using recognized clinical scores like the Psoriasis Area and Severity Index (PASI) and the Investigator's Global Assessment (IGA). These studies observed patient responses over short-term intervals, typically 12 to 16 weeks. The findings describe patterns observed in the studies where proportions of the tested populations reported achieving specific levels of skin clearance. Long-term studies described the maintenance of the reported responses in some patients followed for up to five years. Real-world Evidence (RWE) from observational settings indicates variability in long-term adherence, and research limitations note that results apply only to the populations studied in the trials.

Evidence Overview: Psoriatic Arthritis (PsA) Research

Secukinumab was evaluated in adults and children (age two and older) with active PsA, a condition marked by functional limitations. The research primarily used Phase III Randomized Controlled Trials and extension studies. Studies monitored outcomes related to physical discomfort using the ACR response criteria. Researchers also examined radiographic data to monitor the rate of change in joint structural damage over time. Long-term data described the maintenance of reported responses in patients followed for up to five years. Evidence is limited for specific dosing adjustments, as studies exploring the effect of a higher dose in initial non-responders reported mixed findings.

Evidence Overview: Axial Spondyloarthritis Research (AS and nr-axSpA)

Research was studied for adults with AS and nr-axSpA. Outcomes measured included disease activity and symptoms assessed via the ASAS response criteria and the BASDAI. The research highlights changes measured over time, with long-term studies describing the maintenance of the reported response criteria in cohorts followed for multiple years. Research in cohorts of patients who had previously received anti-TNF- alpha biologics was also evaluated.

Key Limitations and Areas of Uncertainty

Research in Hidradenitis Suppurativa (HS) and Enthesitis-Related Arthritis (ERA) used smaller-scale trials or had follow-up durations that were more limited compared to older indications. For all conditions, data for certain groups remain insufficient, and data are still emerging regarding the long-term functional and structural outcomes for nr-axSpA.

Common questions about Secukinumab (FAQ)

Q: Is secukinumab considered a type of chemotherapy?

Secukinumab is classified as a biologic medicine that works as an Interleukin-17A (IL-17A) inhibitor. It is specifically an immunosuppressant that targets a precise pathway in the immune system. Official product information confirms that it is not classified as a chemotherapy drug.

Q: What happens if I abruptly stop taking secukinumab?

According to official documentation, abruptly stopping treatment may cause your underlying condition to worsen or lead to a disease relapse. The potential benefit of continuing therapy is a factor to consider in the overall treatment plan. Consultation with a healthcare provider is necessary before making any changes to the treatment schedule.

Q: Does secukinumab cause fatigue?

Official product information lists fatigue, or unusual tiredness or weakness, as a common side effect. Persistent or severe fatigue should be noted and discussed with a healthcare professional.

Q: Are there any known interactions between secukinumab and food or dietary supplements?

Regulatory documents indicate no specific reports of direct interactions between secukinumab and foods or dietary supplements. Known interactions primarily involve certain other medicines and vaccines. The prescribing doctor should be informed of all supplements being taken.

Q: What should I do if I experience a reaction at the injection site?

Injection site reactions such as redness, swelling, pain, itching, or burning have been reported. These reactions are generally mild. If a reaction is severe, persistent, or causes concern, consulting the prescribing physician is advised.

Q: Can I drink alcohol while on secukinumab?

Regulatory documents do not state a formal restriction on consuming alcohol while receiving secukinumab. However, caution is generally indicated if other medications, such as methotrexate, are being taken concurrently, or if alcohol affects the underlying condition.

Q: Does secukinumab require any special blood monitoring?

Before starting therapy, official guidelines require mandatory screening for latent tuberculosis (TB). During treatment, monitoring for potential adverse effects such as neutropenia (a low white blood cell count) is typically part of the safety precautions.

Q: Can secukinumab cause liver damage?

Official information indicates that secukinumab has not been directly linked to causing sudden, significant liver injury. However, because it affects the immune system, it carries a potential risk for the reactivation of Hepatitis B in people who are susceptible. Screening for Hepatitis B is a standard procedure before starting therapy, when clinically indicated.

Q: Does secukinumab affect mood or mental health?

Regulatory documents list common side effects such as headache and mention other nervous system events as rare occurrences. However, the official prescribing information does not explicitly state a general effect on overall mood or mental health.

Q: Can I take ibuprofen or other NSAIDs while on secukinumab?

Official interaction checkers and regulatory studies have found no known direct interaction between secukinumab and common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. Review and confirmation of the concurrent use of any medications by a healthcare provider is a necessary precaution.

Q: Does secukinumab increase my risk of cancer?

Clinical trial data, including studies tracking patients for up to five years, indicated that the observed rate of malignancy (cancer) in patients treated with secukinumab was comparable to the expected rate found in the general population. The overall risk reported in these studies was low.

Q: Does secukinumab affect male or female fertility?

Non-clinical animal studies have shown no harmful effects on either male or female fertility. However, because data on human use during pregnancy is limited, the use of effective contraception is indicated for women of childbearing potential.

Q: Are there other brands or biosimilar versions of secukinumab?

Secukinumab is marketed under the brand name Cosentyx. The potential for biosimilar versions to be available may vary by region and regulatory authority. Availability should be confirmed with the local regulatory body or healthcare provider.

Q: How does secukinumab work compared to an anti-TNF biologic?

Secukinumab is a selective Interleukin-17A (IL-17A) antagonist, which means it specifically blocks the IL-17A protein in the inflammatory pathway. Anti-TNF biologics, such as those mentioned in research, block a different protein called Tumor Necrosis Factor-alpha (TNF-alpha). Both are targeted therapies, but they interrupt different pathways in the immune process.

Q: How is secukinumab processed and eliminated by the body?

Secukinumab is a protein that is naturally broken down, or metabolized, into amino acids through the body's usual catabolic processes. Clinical pharmacology data reports that the drug has a long half-life of approximately 27 days, which reflects how long it takes for half of the dose to be eliminated.

Secukinumab injection (pen or syringe) must be stored in the refrigerator at temperatures between 2 C to 8 C (36 F to 46 F).

Storage Requirements

• Do not freeze the medicine; if it has frozen, it must be discarded.
• Keep the product in its original carton to protect it from light until the time of use.
• It is mandatory to keep the medicine out of the sight and reach of children.
• The product must not be shaken.
• Secukinumab can be stored out of the refrigerator, at room temperature (not above 30 C or 86 F), for a maximum of 4 days.

Disposal

All used syringes and pens, as well as any unused or expired product, must be disposed of immediately in an FDA-cleared sharps disposal container. The full container must then be handled according to local waste regulations.